ArticleExperimental and therapeutic medicine2022
Frequency of HLA‑G UTR‑1/UTR‑3/UTR‑7 in women with unexplained recurrent spontaneous abortion.
Article in Experimental and therapeutic medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 5 citations in OpenAlex.
- Reproductive Immunology and Pregnancy 3.0.International journal of molecular sciences · 2023Article
- HLA-G and Recurrent Pregnancy Loss.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Human leukocyte antigen (HLA)-G is an important molecule that maintains maternal-fetal interface tolerance and plays a vital role in a healthy pregnancy. Single-nucleotide polymorphisms in the 3'-untranslated regions (UTR) of the HLA-G gene may differ in women with unexplained recurrent spontaneous abortion (URSA). The present study involved the isolation of genome DNA from peripheral blood leukocytes, Sanger sequencing and analysis of the polymorphism sites in the 3'UTR of the HLA-G gene based on polymerase chain reaction. In total, 261 DNA samples from cases of URSA (n=133), including primary URSA (n=83) and secondary URSA (n=50), and controls (n=128) were evaluated. The present data showed that +3010CC genotype carriers exhibited a higher risk of URSA, while +3187GG genotype carriers exhibited a lower risk. Secondary URSA patients carrying +3010C had a higher risk of URSA, while +3187G carriers exhibited a lower risk of URSA. UTR-1 haplotype carriers may be associated with a reduced risk of primary and secondary URSA. Notably, UTR-3 and UTR-7 could increase the risk of primary and secondary URSA, respectively. The present results showed that HLA-G 3'UTR polymorphisms and haplotypes may be involved in URSA development and be a predictor of pregnancy outcome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.